Link bolsters comms after NICE appraisal

Link Pharmaceuticals is using Spink Consumer Relations to bolster its communications as it prepares to lodge an appeal against a negative NICE appraisal of its brain cancer treatment Gliadel Implants.

Link wants to promote the benefits of the product, a 5p-sized biodegradable disc that administers a chemotherapy drug directly to a tumour site after the tumour has been removed.

The company wants to encourage clinicians to continue to use the product for newly diagnosed patients, despite NICE, on 28 April, recommending against such use on the NHS.

The product has been licensed for use in the UK since 2001 to treat recurrent brain tumour patients, an area in which NICE has yet to publish guidance.

Link has formerly worked with Spink on a project basis but has now hired the agency to handle a 'comprehensive' 12-month campaign.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in